Prostate Cancer

"We've really found that [same-day discharge is] a reasonable option and something that many patients are really pleased by," says Brian R. Lane, MD, PhD, FACS.

The phase 1/2 trial is assessing the safety, tolerability, radiation dosimetry, and preliminary anti-tumor activity of 225Ac-rhPSMA-10.1 in men with mCRPC.

"By helping them see what could be going on with their health and knowing when to reach out for help, we think that's a fantastic way to begin to change the paradigm when it comes to men and prostate cancer in the US," says Motolani Adedipe, PhD, DPh, MSc.

The key opinion leaders explore the challenges and limitations associated with using prostate-specific antigen (PSA) as a biomarker for prostate cancer detection and monitoring.

The panel of experts in prostate cancer offers a comprehensive overview of prostate cancer diagnosis, emphasizing the role of prostate-specific antigen (PSA) testing in screening for the disease.

"We did see a rise in 2020, and that's been kind of maintained in 2021 and 2022, but overall, it looked like a pretty low rate," says Brian R. Lane, MD, PhD, FACS.

Data from the study showed that 45% of biopsies with benign results or low-grade cancers could be reduced overall by using Stockholm3 compared with PSA.

Stephen Freedland, MD, reviews findings from the EMBARK study, which investigated enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.

3. Terence Friedlander, MD, provides clinical insights on factors that inform the role for androgen deprivation therapy in the treatment of patients with localized or locally advanced prostate cancer.

“Our data suggest that an MRI can show suspicious lesions based on size and markers of tumor aggression, which may help doctors differentiate a treatment path for these patients," says Kiran R. Nandalur, MD.

"When it came down to linking the clinical information with both biopsy reports as well as the prostatectomy pathology reports, we didn't have much of a challenge with that," says Randy A. Vince Jr, MD, MS.

The prognostic test has now been validated in patients who have undergone active surveillance, radiation therapy, or had a radical prostatectomy.

“So, rather than waiting for men to proactively seek out mental health supports once they’ve been diagnosed with prostate cancer, we should be offering supports at the time of diagnosis and throughout treatment," says Kerri Beckmann, PhD.

“We will do exactly what we have done in terms of prototype of our processes, our tools, our design, and how we follow these patients up, and expand this from 10,000 men in less than 2 years to 1 million men in next 10 years,” says Ashutosh K. Tewari, MD.

Kyrollis Attalla, MD, remarks on emerging imaging technologies for patients with prostate cancer and the growing pool of candidates for focal therapy.

An expert on prostate cancer discusses how fusion-guided biopsy can help determine patient eligibility for focal therapy.

The grants will support research evaluating ATAD2 in advanced prostate cancer and 6MP in hereditary leiomyomatosis and renal cell cancer.

The CPT code 76377 may be used for ProstatID when the software is used in conjunction with a suitable CT, MRI, or a transrectal ultrasound.

Experts on prostate cancer discuss the heterogeneity of the disease and the rationale for using medications with different mechanisms of action, including androgen deprivation therapy.

Lawrence Karsh, MD, FACS, introduces a discussion on prostate cancer and androgen deprivation therapy with an overview of how the treatment landscape has changed in recent years.

"This study demonstrates that for up to 10 years after diagnosis, approximately 50% of men with low-risk prostate cancer can safely remain on AS, without cancer progression or treatment, since less than 1% died of prostate cancer," writes Badar M. Mian, MD.

"This study was looking at the incidence of cognitive impairment and/or manual dexterity disorder diagnoses in men who underwent an artificial urinary sphincter after treatment for prostate cancer," says Jacqueline Zillioux, MD.

"By using our technique, and really preserving that urethral length really well, it seems to help those patients in particular to have better outcomes," David I. Lee, MD, FACS.

“This highlights a need for physicians to better integrate patient preferences into their treatment recommendations," says Jonathan Bergman, MD, MPH.

Kyrollis Attalla, MD, describes the role of fusion-based biopsies in active surveillance for patients with prostate cancer and how this technology has improved monitoring and treatment strategies.